Treatment with exenatide, a GLP-1 receptor agonist, was comparable to placebo in slowing the rate of Parkinson’s disease progression over 96 weeks of treatment, according to a phase 3 study ...

In the meantime, many other diseases have been associated with mutations in the MAPT gene, including Pick's disease, progressive supranuclear palsy, and pallidopontonigral degeneration.

Researchers from the Cleveland Clinic Genome Center have successfully applied advanced artificial intelligence (AI) genetics ...

Even if the initial buildup is treated, the disease's progression can cause recurrences. Learn more about the symptoms of Niemann-Pick disease now. Niemann-Pick disease patients may experience ...

Researchers have successfully applied advanced artificial intelligence (AI) genetics models to Parkinson's disease. Researchers identified genetic factors in progression and FDA-approved drugs that ...